AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 172 min read$PVLA

Goin Kathleen sold $642K of PVLA

Goin Kathleen (Chief Operating Officer) sold 4,302 shares of PALVELLA THERAPEUTICS, INC. (PVLA) at an average of $149.28 ($147.14–$150.25, $0.64M total) across 4 trades on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Goin Kathleen
Published Jul 17, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 17, 2026, 8:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PVLA
Neutral
high confidence
Mentioned
$PVLA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PVLANeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale amount, share count, trade dates, and confirmation of a pre-arranged 10b5-1 plan; this typically has limited fundamental impact.

02

Market read

Insider selling can influence short-term sentiment, but the 10b5-1 framing suggests the trades were scheduled rather than reactive.

03

What to watch

Traders may overreact to insider sales; without accompanying operational or financial updates, the signal is mostly sentiment-level.

Relevance 4/10Novelty 3/10Timing: today’s SEC Form 4 filing (filed 2026-07-17)

Background

The article is an SEC Form 4 insider transaction for Palvella Therapeutics, Inc. (PVLA) by its COO.

Company-level read

Ticker impact

$PVLANeutralHigh confidence
Context

Palvella Therapeutics COO Goin Kathleen sold 4,302 shares in an open-market transaction totaling about $642,191, per Form 4 filed today.

Expected impact

Likely limited near-term impact; any reaction should be muted given the stated pre-arranged 10b5-1 plan.

Evidence & confidence

The filing provides transaction size, dates, and confirms a pre-arranged Rule 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Sector

No direct sector read-through; this is a single-company insider transaction.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, the disclosure may be routine and not signal reduced confidence.

Key entities

  • issuer
    Palvella Therapeutics, Inc.

    Subject of the Form 4 insider sale disclosure.

  • insider
    Goin Kathleen

    Chief Operating Officer who sold shares under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PVLA insider trading history →

Related articles

OCT 28
$PVLAMedAI 8/10

FDA grants priority review to Palvella’s lymphatic malformation therapy

Palvella Therapeutics (NASDAQ:PVLA) announced FDA Priority Review for QTORIN 3.9% gel to treat microcystic lymphatic malformations, with a target action date of February 28, 2027. The application is based on positive Phase 3 SELVA study results, showing significant efficacy and a good safety profile. The therapy has received Breakthrough Therapy, Fast Track, and Orphan Drug designations. Palvella plans a potential U.S. launch in early 2027, pending approval.

investing.com3 min
OCT 28
$PVLAMedAI 8/10

Palvella Therapeutics Gets Priority Review for QTORIN Rapamycin NDA

Palvella Therapeutics (PVLA) received FDA acceptance and Priority Review for its QTORIN rapamycin NDA, targeting a February 28, 2027 decision. The NDA seeks approval to treat microcystic lymphatic malformations, a condition with no current FDA-approved therapies. Phase 3 SELVA results showed statistical significance across all efficacy endpoints. Palvella plans a potential U.S. launch in early 2027 if approved.

tradingview.com1 min
OCT 28
$PVLAMedAI 8/10

Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set

PALVELLA THERAPEUTICS, INC. (PVLA) filed an SEC Form 8-K — Other Events. Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set QTORIN™ rapamycin could become the first FDA-approved therapy for microcystic lymphatic malformations, a serious, lifelong rare disease affecting an esti

SEC EDGAR 8-K2 min
OCT 20
$PVLAMed

Palvella at Chardan conference: rare-disease push nears launch

Palvella Therapeutics (PVLA) presented its rare-disease strategy at Chardan's conference, targeting a commercial launch in 2025. The company raised $230M in 2024, filed an NDA for QTORIN rapamycin, and expects an FDA decision by late October. Palvella is expanding its pipeline to six indications by year-end, with a focus on skin and vascular anomaly diseases. Management anticipates peak sales of $1B-$3B for its lead programs.

investing.com3 min